GE HealthCare stock (US36266G1076): Medical imaging leader faces headwinds in 2026

GE HealthCare stock has declined sharply in 2026, with YTD losses near 25%, as investors weigh its medical imaging strength against valuation and sector headwinds.

GE HealthCare stock has come under pressure in 2026, with year?to?date performance among the weakest in its peer group as the company navigates a challenging healthcare equipment environment. Shares of GE HealthCare Technologies Inc. (ticker: GEHC) are down roughly 25% year to date on Nasdaq, according to market data compiled by Saxo Bank as of early May 2026, reflecting both sector?wide caution and company?specific execution concerns.

Analyst coverage and valuation models suggest that the stock may be trading below some intrinsic?value estimates, yet near?term sentiment remains cautious. A third?party model cited by Danelfin in early 2026 indicates a long?term EPS growth expectation of about 10.5% over the next five years, while also flagging that the stock’s YTD performance sits in the bottom 20% of its universe, implying that the market is pricing in a relatively high risk premium or slower near?term growth.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GE HealthCare Technologies Inc.
• Sector/industry: Healthcare / Medical technology
• Headquarters/country: United States
• Core markets: United States, Europe, Asia and other developed healthcare systems
• Key revenue drivers: Medical imaging hardware, service contracts, contrast agents and digital health software
• Home exchange/listing venue: Nasdaq (ticker: GEHC)
• Trading currency: USD

GE HealthCare: core business model

GE HealthCare is a leading global provider of medical imaging and monitoring technologies, spun off from General Electric in early 2023. The company designs, manufactures and services a broad portfolio of equipment used in hospitals and clinics, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound and X?ray systems, as well as patient?monitoring devices and related software platforms.

A key feature of GE HealthCare’s model is its mix of one?time equipment sales and recurring revenue streams. Industry and broker commentary note that roughly half of the company’s revenue is recurring, derived from service contracts, consumables such as contrast agents and digital solutions that support clinical workflows and data management. This structure aims to smooth cash flows and provide visibility into future earnings, even as capital?equipment cycles in healthcare can be lumpy.

Main revenue and product drivers for GE HealthCare

Within GE HealthCare’s portfolio, imaging hardware remains the largest revenue driver, with MRI and CT systems typically representing the highest?value segments. The company competes with other large med?tech players in these markets, where pricing pressure, regulatory scrutiny and hospital budget constraints can weigh on margins and order intake.

Service contracts and consumables are increasingly important as recurring?revenue pillars. Broker analyses estimate that service alone accounts for about one?third of total revenue, while contrast agents and related pharmaceutical diagnostics contribute roughly 10–15%, and digital solutions add just over 5%. This mix supports higher gross margins on the recurring side and can partially offset volatility in new?equipment orders, especially in periods of slower hospital capital spending.

Why GE HealthCare matters for US investors

For US investors, GE HealthCare offers exposure to a core segment of the domestic healthcare infrastructure, where demand for advanced imaging and monitoring is tied to aging demographics, chronic?disease prevalence and ongoing hospital modernization. The company’s Nasdaq listing and predominantly US?dollar?denominated cash flows make it a liquid, sector?specific play within the broader healthcare technology universe.

At the same time, the stock’s recent underperformance highlights the sensitivity of medical?equipment names to macroeconomic and policy factors, including interest?rate levels, reimbursement trends and hospital capital budgets. US?based retail investors considering GE HealthCare must weigh its established market position and recurring?revenue profile against valuation multiples and sector?specific risks.

Conclusion

GE HealthCare remains a major player in global medical imaging and monitoring, with a diversified product set and a growing share of recurring revenue from service, contrast agents and digital solutions. The stock’s sharp decline in 2026 reflects investor concerns about near?term growth, valuation and broader healthcare?equipment headwinds, even as some models suggest potential upside if execution and macro conditions improve.

For US investors, the name offers a way to participate in long?term healthcare?technology trends, but also exposes them to cyclical capital?spending cycles, regulatory risk and competitive pressures. A balanced view would recognize both the company’s entrenched position in key imaging segments and the uncertainties that can weigh on earnings and sentiment in the near term.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.